APA (7th ed.) Citation

Klempner, S. J., Maron, S. B., Chase, L., Lomnicki, S., Wainberg, Z. A., & Catenacci, D. V. (2019). Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis. The oncologist (Dayton, Ohio), 24(4), 475-482. https://doi.org/10.1634/theoncologist.2018-0602

Chicago Style (17th ed.) Citation

Klempner, Samuel J., Steven B. Maron, Leah Chase, Samantha Lomnicki, Zev A. Wainberg, and Daniel V.T Catenacci. "Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis." The Oncologist (Dayton, Ohio) 24, no. 4 (2019): 475-482. https://doi.org/10.1634/theoncologist.2018-0602.

MLA (9th ed.) Citation

Klempner, Samuel J., et al. "Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis." The Oncologist (Dayton, Ohio), vol. 24, no. 4, 2019, pp. 475-482, https://doi.org/10.1634/theoncologist.2018-0602.